Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update

Página do item simplificado
dc.citation.issue18]
dc.citation.volume35]
dc.contributor.authorLehrnbecher, Thomas
dc.contributor.authorRobinson, Paula
dc.contributor.authorFisher, Brian
dc.contributor.authorAlexander, Sarah
dc.contributor.authorAmmann, Roland A.
dc.contributor.authorBeauchemin, Melissa
dc.contributor.authorCarlesse, Fabianne [UNIFESP]
dc.contributor.authorGroll, Andreas H.
dc.contributor.authorHaeusler, Gabrielle M.
dc.contributor.authorSantolaya, Maria
dc.contributor.authorSteinbach, William J.
dc.contributor.authorCastagnola, Elio
dc.contributor.authorDavis, Bonnie L.
dc.contributor.authorDupuis, L. Lee
dc.contributor.authorGaur, Aditya H.
dc.contributor.authorTissing, Wim J. E.
dc.contributor.authorZaoutis, Theo
dc.contributor.authorPhillips, Robert
dc.contributor.authorSung, Lillian
dc.coverageAlexandria
dc.date.accessioned2020-06-26T16:30:36Z
dc.date.available2020-06-26T16:30:36Z
dc.date.issued2017
dc.description.abstractPurposeTo update a clinical practice guideline (CPG) for the empirical management of fever and neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients.MethodsThe International Pediatric Fever and Neutropenia Guideline Panel is a multidisciplinary and multinational group of experts in pediatric oncology and infectious diseases that includes a patient advocate. For questions of risk stratification and evaluation, we updated systematic reviews of observational studies. For questions of therapy, we conducted a systematic review of randomized trials of any intervention applied for the empirical management of pediatric FN. The Grading of Recommendation Assessment, Development and Evaluation approach was used to make strong or weak recommendations and to classify levels of evidence as high, moderate, low, or very low.ResultsRecommendations related to initial presentation, ongoing management, and empirical antifungal therapy of pediatric FN were revieweden
dc.description.abstractthe most substantial changes were related to empirical antifungal therapy. Key differences from our 2012 FN CPG included the listing of a fourth-generation cephalosporin for empirical therapy in high-risk FN, refinement of risk stratification to define patients with high-risk invasive fungal disease (IFD), changes in recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolonged FN.ConclusionChanges to the updated FN CPG recommendations will likely influence the care of pediatric patients with cancer and those undergoing hematopoietic stem-cell transplantation. Future work should focus on closing research gaps and on identifying ways to facilitate implementation and adaptation.en
dc.description.affiliationGoethe Univ Frankfurt, Hosp Children & Adolescents, Frankfurt, Germany
dc.description.affiliationUniv Childrens Hosp, Munster, Germany
dc.description.affiliationPediat Oncol Grp Ontario, Toronto, ON, Canada
dc.description.affiliationHosp Sick Children, Toronto, ON, Canada
dc.description.affiliationChildrens Hosp Philadelphia, Philadelphia, PA 19104 USA
dc.description.affiliationUniv Bern, Bern Univ Hosp, Bern, Switzerland
dc.description.affiliationColumbia Univ, Herbert Irving Canc Ctr, New York, NY USA
dc.description.affiliationUniv Fed Sao Paulo, GRAACC, Pediat Oncol Inst, Sao Paulo, Brazil
dc.description.affiliationPeter MacCallum Canc Ctr, Melbourne, Vic, Australia
dc.description.affiliationMonash Childrens Hosp, Clayton, Vic, Australia
dc.description.affiliationUniv Chile, Hosp Luis Calvo Mackenna, Santiago, Chile
dc.description.affiliationDuke Univ, Med Ctr, Durham, NC USA
dc.description.affiliationIst Giannina Gaslini, Genoa, Italy
dc.description.affiliationHigh Tor Ltd, Nassau, Bahamas
dc.description.affiliationSt Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
dc.description.affiliationUniv Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
dc.description.affiliationLeeds Teaching Hosp, NHS Trust, Leeds, W Yorkshire, England
dc.description.affiliationUniv York, York, N Yorkshire, England
dc.description.affiliationUnifespUniv Fed Sao Paulo, GRAACC, Pediat Oncol Inst, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCanadian Institutes of Health Research
dc.description.sponsorshipGarron Comprehensive Cancer Centre
dc.description.sponsorshipIDCanadian Institutes of Health Research
dc.description.sponsorshipIDGarron Comprehensive Cancer Centre
dc.format.extent2082-+
dc.identifierhttp://dx.doi.org/10.1200/JCO.2016.71.7017]
dc.identifier.citationJournal Of Clinical Oncology. Alexandria, v. 35, n. 18, p. 2082-+, 2017.
dc.identifier.doi10.1200/JCO.2016.71.7017
dc.identifier.fileWOS000403583700014.pdf
dc.identifier.issn0732-183X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/53648
dc.identifier.wosWOS:000403583700014
dc.language.isoeng
dc.publisherAmer Soc Clinical Oncology
dc.relation.ispartofJournal Of Clinical Oncology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleGuideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Updateen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000403583700014.pdf
Tamanho:
609.71 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos